Get the SPI Wire

JAGUAR HEALTH, INC.

NASDAQ:JAGX
Annual Meeting

of Shareholders

MEETING DATE

11/06/2026
DEF 14A FILED
10/08/2026
PUBLISHED
10/08/2026 8:25 pm
TIME TO PUBLISH
10/10/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:JAGX · CUSIP 47010C854 · CLASS voting common stock, par value $0.0001 per share (the “Common Stock”); Series Q Perpetual Preferred Stock, par value $0.0001 per share (the “Series Q Preferred Stock”) · CIK 0001585608

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

1
FOR
5
AGAINST
0
WITHHOLD
6
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
Approving, for purposes of Nasdaq Listing Rules 5635(b) and 5635(d), the issuance of shares of the Company’s Common Stock issuable upon exchange of shares of the Company’s Series Q Preferred Stock and the CVP Debt issued to certain affiliates of Chicago Venture Partners, L.P. (“CVP”).
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states current stockholders would own a smaller proportionate interest and have less ability to influence corporate decisions.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
Approving, for purposes of Rule 5635(d), the repricing of certain warrants issued to investors to purchase an aggregate of up to 4,052 shares of Common Stock with exercise prices ranging from $525.00 to $3,996.60 per share (the “Investor Warrants”), so that each of the Investor Warrants has a new exercise price equal to $1.00 per share, which Investor Warrants when exercised will also (i) entitle such investors to receive up to 45,511 shares of Common Stock from the Series O Preferred Stock Dividend and (ii) be expected to entitle such investors to receive up to 20,260 shares of Common Stock from the Series R Preferred Stock Dividend.
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states exercise would reduce current stockholders’ proportionate interest and ability to influence corporate decisions.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
Approving an amendment and restatement of the Company’s 2014 Stock Incentive Plan (the “2014 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan to 378,859, which represents 14% of the issued and outstanding shares of Common Stock on a fully diluted basis as of September 30, 2026.
compensation
Contested
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the 2014 Plan could run out of available shares as soon as the third quarter of 2026.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
Approving the Thirteenth Amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”), to effect a reverse stock split of the Company’s issued and outstanding shares of Common Stock at a ratio not less than 1-for-2 and not greater than 1-for-150, the exact ratio to be set within that range at the discretion of the Company’s Board and publicly announced by the Company on or before the one-year anniversary of the approval of this proposal.
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states the reverse split would increase the board’s ability to issue authorized and unissued shares without further stockholder action.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
Approving an amendment to that certain common stock purchase agreement, dated June 9, 2026, by and between the Company and C/M Capital, to reduce the Floor Price (as defined therein) from $16.50 per share to $1.10 per share.
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states shares issued to C/M Capital will result in dilution to existing common stockholders.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.
6
Approving one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve proposals 1, 2, 3, 4, and 5.
other
Contested
Against
Board FOR · Duopoly unknown — ⚠ Divergence flagged

Filing states the proposal would permit adjournments to solicit additional proxies in favor of Proposals 1, 2, 3, 4, and 5.

Divergence: 1 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

37122ddf6ea413232e0f7b9e17b0d3346e45535ccbd7a5dc073e500df8641ae7

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates